|
Contents
|
|
|
|
Astrocytomas
|
|
|
|
Mathieu NT, Genet D, Labrousse F, Bouillet P, Denes
SL, Martin J, Labourey JL, Venat L, Clavere P, Moreau JJ
Pre-irradiation chemotherapy for
newly diagnosed high grade astrocytoma
Anticancer Res. 2004 Mar-Apr;24(2C):1249-53
|
|
|
Brain
Tumors
|
|
|
|
William J. Bodell,
Alexander P. Bodell, Donald D. Giannini
Levels and distribution of BCNU in GBM tumors
following intratumoral injection of DTI-015 (BCNU-ethanol)
Neuro-oncol 2006, Epub 2006 Oct 3. DOI:10.1215/15228517-2006-014
|
|
William J. Bodell, Donald
D. Giannini, Saira
Singh, Dennis
Pietronigro, Victor A. Levin
Formation
of DNA adducts and tumor growth delay following intratumoral administration of
DTI-015
Journal of Neuro-Oncology,
62 (3): 251-258, May
2003
|
|
Plowman
J,
Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR
Preclinical
antitumor activity of temozolomide in mice: efficacy against human brain tumor
xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea
Cancer Res 1994 Jul
15;54(14):3793-9
|
|
Prados MD,
Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE,
Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA,
Gutin PH, Phillips TL, Wilson CB
Radiation therapy and hydroxyurea followed by the
combination of 6-thioguanine and BCNU for the treatment of primary malignant
brain tumors
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63
|
|
|
Glioblastoma
|
|
|
|
Balana C,
Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P,
Sanchez JJ, Rosell R
O(6)-methyl-guanine-DNA
methyltransferase Methylation in Serum and Tumor DNA Predicts Response to
1,3-Bis(2-Chloroethyl)-1-Nitrosourea but not to Temozolamide Plus
Cisplatin in Glioblastoma Multiforme
Clin Cancer Res
2003 Apr;9(4):1461-8
|
|
|
Barrié M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X,
Hoang-Xuan K, Braguer D, Martin PM, Peragut JC, Grisoli F, Chinot O.
Temozolomide in combination with BCNU before and after radiotherapy in
patients with inoperable newly diagnosed glioblastoma multiforme.
Ann
Oncol. 2005 Jul;16(7):1177-84. Epub 2005 Apr 27.
.JPG) Abstract |
.png)
Reprint |
.gif)
Related articles
|
|
Lorena Bissola, Marica Eoli, Francesca Menghi, Bianca Pollo, Antonio
Silvani, Giovanni Broggi, Amerigo Boiardi, Gaetano Finocchiaro
MGMT promoter hypermethylation is more frequent in secondary
glioblastomas and is independent from other prognostic factors
Proceedings of the AACR, Volume 45, March 2004. Abstract
Number: 1077
|
|
Alba
Ariela Brandes, Mario Ermani, Umberto Basso, Lara Maria Pasetto, Francesca
Vastola, Franco Berti, Silvia Berlucchi, Pietro Amistà, Antonello Rotilio,
Silvio Monfardini
Procarbazine
Prior to and Concomitant with BCNU in Patients with Glioblastoma at First
Relapse: a Phase II Study
ASCO
Proceedings, 2001 Annual Meeting, Abstract
|
|
R. Cardinale, M. Won,
A. Choucair, M. Gillin, A. Chakravarti,
C. Schultz, L. Souhami, A. Chen, H.
Pham and M. Mehta
A phase II trial of accelerated radiotherapy using weekly stereotactic
conformal boosts for supratentorial glioblastoma multiforme. RTOG-0023
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1511.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1511
|
|
|
Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD,
Olivi A, Quiñones-Hinojosa A, Brem H.
The
efficacy of carmustine wafers for older patients with glioblastoma
multiforme: prolonging survival.
Neurol Res. 2011 Sep;33(7):759-64.
Abstract |
Reprint |
Related articles
|
|
O. Chinot, M. Barrie, C. Couprie, H. Dufour, D. Figarella, X. Muracciole,
D. Braguer, K. Hoang-Huan, J.-C. Peragut, F. Grisoli
Preradiation combination of
temozolomide (TMZ) and BCNU as primary treatment before radiotherapy (RT)
in inoperable newly diagnosed glioblastoma multiforme (GBM)
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 431
|
|
|
Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid
JM, McGovern RM,
Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich
DA, Morton RF, Wender DB, Buckner JC
Phase
II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for
newly diagnosed GBM.
J
Neurooncol. 2010 Aug;99(1):73-80. Epub 2010 Jan 9
Abstract |
.png)
Full Text |
Reprint |
Related articles
|
|
K. A. Jaeckle, K. V.
Ballman, P. Schomberg, J. Uhm, B.
Schiethauer, C. Giannini, S. Felton, P.
Brown, B. C. Jan NCCTG
N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly
diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG)
study
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1514
|
|
Khoshyomn
S, Nathan D, Manske GC, Osler TM, Penar PL
Synergistic
effect of genistein and BCNU on growth inhibition and cytotoxicity of
glioblastoma cells.
J
Neurooncol 2002 May;57(3):193-200
Abstract |
Reprint |
Related articles
|
|
C.
Linassier, M. Ben Hassel, D. Figarella-Branger, J.-O. Bay, H.
Bourgeois, T. Lesimple, J.-P. Cottier, L. Taillandier, R. Delepine, D.
Frappaz
Phase
III study comparing high-dose BCNU with autologous blood stem cell support
versus standard dose BCNU, in combination with radiotherapy after gross
total resection in patients with supratentorial glioblastoma
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 399
|
|
|
Mihaliak
AM, Gilbert CA, Li L, Daou MC, Moser RP, Reeves A, Cochran BH, Ross AH.
Clinically relevant doses of chemotherapy agents reversibly block
formation of glioblastoma neurospheres
Cancer Lett. 2010 Apr 30;. [Epub ahead of print]
Abstract
|
|
Timothy
J Moynihan, Judith R O'Fallon, J. E Krook, Paula Schomberg, Robert P
Dinapoli, I. Kazem, Bernd Scheithauer, Jan C Buckner
A
phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral
etoposide combined with radiation therapy in the treatment of glioblastoma (GBM)
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract
No. 306
|
|
Napolitano
M, Keime-Guibert F, Monjour A, Lafitte C, Ameri A, Cornu P, Broet
P, Delattre JY
Treatment
of supratentorial glioblastoma multiforme with radiotherapy and a combination of
BCNU and tamoxifen: a phase II study
J Neurooncol 1999;45(3):229-35
|
|
|
Nicolardi
L, Deangelis
LM
Response to chemotherapy of a radiation-induced
glioblastoma multiforme
J
Neurooncol. 2005 Nov 29;1-3 [Epub ahead of print]
|
|
|
Pan
E, Mitchell SB, Tsai JS
A retrospective study of the safety of BCNU wafers with concurrent
temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed
glioblastoma patients
J Neurooncol.
2008 Apr 4; [Epub ahead of print]
Abstract
|
|
Schold
SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM,
Fulton D, Fink KL, Prados MD.
A
phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a
North American Brain Tumor Consortium study
Neuro-oncol
2000 Jan;2(1):34-9
|
|
|
Salmaggi A, Duri S, Silvani
A, Gaviani P, Milanesi I, Casali C, Di Meco F.
Loco-regional
treatments in first-diagnosis glioblastoma: literature review on association
between Stupp protocol and Gliadel.
Neurol Sci. 2011
Oct 8. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, Dimeco F, Milanesi IM,
Erbetta A, Boiardi A, Fariselli L, Salmaggi A
Cisplatinum
and BCNU chemotherapy in primary glioblastoma patients
J Neurooncol.
2009 Feb 11. [Epub ahead of print]
Abstract
|
|
|
Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R,
Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ
Jr.
Randomized
comparison of stereotactic radiosurgery followed by conventional
radiotherapy with carmustine to conventional radiotherapy with carmustine
for patients with glioblastoma multiforme: report of Radiation Therapy
Oncology Group 93-05 protocol.
Int
J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60.
Abstract |
Related articles
|
|
|
Vinjamuri M, Adumala RR, Altaha R, Hobbs GR,
Crowell EB Jr.
Comparative analysis of temozolomide (TMZ) versus 1,3-bis
(2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma
multiforme (GBM) patients
J Neurooncol. 2008 Sep 24; [Epub ahead of print]
Abstract
|
|
Carmustine implants
|
|
|
|
Bock
HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R,
Rainov N, Kantelhardt SR, Rohde V, Giese A.
First-line treatment of malignant glioma with carmustine implants followed
by concomitant radiochemotherapy: a multicenter experience
Neurosurg Rev. 2010 Aug 13;. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
Alf
Giese, Thomas Kucinski, Ulrich Knopp, Roland Goldbrunner, Wolfgang Hamel,
H.M. Mehdorn, Jörg
C. Tonn, Dana Hilt, Manfred
Westphal
Pattern of Recurrence following Local Chemotherapy
with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma
Journal of Neuro-Oncology, 66 (3): 351-360, February 2004
|
|
|
Kleinberg
L, Yoon G, Weingart JD, Parisi M, Olivi A, Detorie NA, Chan TA
Imaging After GliaSite Brachytherapy: Prognostic MRI Indicators of Disease
Control and Recurrence
Int J Radiat Oncol Biol Phys. 2009 Apr 23;. [Epub ahead of print]
Abstract
|
|
|
McGirt MJ, Than KD, Weingart JD, Chaichana KL,
Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa
A
Gliadel
(BCNU) wafer plus concomitant temozolomide therapy after primary resection
of glioblastoma multiforme
J Neurosurg.
2008 Dec 1. [Epub ahead of print]
Abstract
|
|
|
Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich
JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon
JE 2nd, Threatt S, Friedman HS
Phase
II trial of Gliadel plus O6-benzylguanine in adults with recurrent
glioblastoma multiforme
Clin
Cancer Res. 2009 Feb 1;15(3):1064-8
Abstract
|
|
|
Smith KA, Ashby LS, Gonzalez F, Brachman DG, Thomas T, Coons SW, Battaglia
M, Scheck A
Prospective
trial of gross-total resection with Gliadel wafers followed by early
postoperative Gamma Knife radiosurgery and conformal fractionated
radiotherapy as the initial treatment for patients with radiographically
suspected, newly diagnosed glioblastoma multiforme
J Neurosurg.
2008 Dec;109 Suppl:106-17
Abstract
|
|
Subach
BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D
Morbidity and survival after
1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent
glioblastoma: a retrospective case-matched cohort series
Neurosurgery
1999 Jul;45(1):17-22
|
|
Emil L. Weber and Eric A. Goebel
Cerebral edema associated with Gliadel wafers: Two case studies
Neuro-Oncology, Volume
7, Number 1, Pages 84 -- 89, January 2005. (Abstract+)
|
|
Recurrent
Tumors
|
|
|
A. A. Brandes, MD, A. Tosoni, MD, P.
Amistà, MD, L. Nicolardi, MD, D. Grosso, RN, F.
Berti, MD and M. Ermani, MD
How effective is BCNU in recurrent
glioblastoma in the modern era? A phase II trial
Neurology, Oct 12, 2004;63:1281-1284
|
|
A. A. Brandes, A. Tosoni, M.
Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S.
Monfardini, M. Ermani
Second line BCNU plus CPT-11 chemotherapy in
recurrent glioblastoma (GBM): Phase II study of GICNO (Italian
Neuro-Oncology Group)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516
|
|
|
Figueiredo
EG, Faria JW, Teixeira MJ.
Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis
(2-chloroethyl)-1-nitrosourea].
Arq Neuropsiquiatr. 2010 Oct;68(5):778-82.
Abstract |
Reprint |
Related articles
|
|
|
Michael D. Prados, W.K. Alfred Yung, Howard A. Fine,
Harry S. Greenberg, Larry Junck, Susan M. Chang, M. Kelly Nicholas, H. Ian
Robins, Minesh P. Mehta, Karen L. Fink, Kurt A. Jaeckle, John Kuhn,
Kenneth R. Hess, and S. Clifford Schold Jr.
Phase 2 study of BCNU and temozolomide for
recurrent glioblastoma multiforme: North American Brain Tumor Consortium
study
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 33 -- 37
|
|
|
Reithmeier
T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G
BCNU
for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic
factors
BMC Cancer.
2010 Feb 2;10(1):30. [Epub ahead of print]
Abstract |
Full Text |
Reprint
|
|
|
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier
AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ,
Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T
Randomized
Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent
Glioblastoma: EORTC Brain Tumor Group Study 26034
J
Clin Oncol. 2009 Feb 9. [Epub ahead of print]
Abstract
|
|
|
Gliomas
|
|
|
|
Aas AT,
Brun A, Pero RW, Salford LG.
Chlorpromazine
in combination with nitrosourea inhibits experimental glioma growth.
Br J Neurosurg
1994;8(2):187-92
|
|
Mary
L Affronti, David Reardon, Deborah Allen, Rodney Beason, Sridharan
Gururangan, Allan Friedman, James Herndon, Susanne Jackson, Roger McLendon,
Jennifer Quinn, Jeremy Rich, John Sampson, Amy Walker, Darell D Bigner, Henry
Friedman
A
phase II study of CPT-11 plus BCNU for adults with high grade glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2091
|
|
Beith
J., Cook R., Robinson B., Levi J., Bell D., Wheeler H.
Modulation of resistance to BCNU by depleting
MGMT activity with procarbazine in patients with relapsed high-grade
gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1375
|
|
|
Blumenthal DT, Rankin C, Eyre HJ, Livingston RB,
Spence AM, Stelzer KJ, Rushing EJ, Berger MS, Rivkin SE, Cohn AL, Petersdorf
SH
External beam irradiation and the combination of cisplatin and carmustine
followed by carmustine alone for the treatment of high-grade glioma: a phase
2 Southwest Oncology Group trial
Cancer. 2008 Jun 2. [Epub
ahead of print]
Abstract
|
|
Bowles
AP Jr, Pantazis CG, Wansley W
Use of
verapamil to enhance the antiproliferative activity of BCNU in human glioma
cells: an in vitro and in vivo study
J
Neurosurg 1990 Aug;73(2):248-53
|
|
Chang SM, Prados MD, Yung WK, Fine H, Junck L,
Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K,
Schold C
Phase II study of neoadjuvant 1, 3-bis
(2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed
anaplastic glioma: a North American Brain Tumor Consortium Trial
Cancer. 2004 Apr 15;100(8):1712-6.
|
|
S.
M.
Chang, W. K. A. Yung, J. Kuhn, D. Schiff, H. Fine, M. Mehta, I.
Robins, L. Junck, K. Hess, M. Prados
Phase II study of neoadjuvant
BCNU and temozolomide for newly diagnosed anaplastic glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
413
|
|
Engelhard
HH
The
role of interstitial BCNU chemotherapy in the treatment of malignant glioma
Surg Neurol. 2000 May; 53(5): 458-64.
|
|
Esteller
M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V,
Baylin SB, Herman JG
Inactivation of the DNA-repair gene MGMT and
the clinical response of gliomas to alkylating agents
N Engl J Med 2000 Nov
9;343(19):1350-4
|
|
Fine HA,
Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf
CB
Phase
II trial of thalidomide and carmustine for patients with recurrent high-grade
gliomas
J Clin Oncol. 2003 Jun 15;21(12):2299-304
|
|
Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC,
Bigner DD, Dolan ME
O6-benzylguanine-mediated
enhancement of chemotherapy
Mol Cancer Ther 2002
Sep;1(11):943-8
|
|
Maria
Gonzalez Cao, Javier Aristu, Marta Santisteban, Jose M Ordonez, Jose M
Aramendia, Ignacio Bilbao, Oscar Fernandez, Salvador Martin Algarra
Phase
II trial of BCNU, temozolamide (TMZ) plus intraarterial cisplatin (CDDP) in
unresectable or recurrent high grade glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract
No.
2099
|
|
Hamstra DA, Moffat BA, Hall DE, Young JM,
Desmond TJ, Carter J, Pietronigro D, Frey KA, Rehemtulla A, Ross BD
Intratumoral injection of BCNU in
ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study
J Neurooncol. 2005 Jul;73(3):225-38.
|
|
|
Jenkinson
MD, Smith TS, Haylock B, Husband D, Shenoy A, Vinjamuri S, Walker C,
Pietronigro D, Warnke PC
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated
adult malignant glioma
J Neurooncol. 2010 Jan 10;. [Epub ahead of print]
Abstract
|
|
Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA,
Li K, Olivi A, Wharam MD, Brem H
Clinical course and pathologic findings after
Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for
patient management
Cancer Invest. 2004;22(1):1-9.
|
|
|
La Rocca RV, Mehdorn HM.
Localized BCNU chemotherapy and the multimodal management of malignant
glioma
Curr Med Res Opin. 2009 Jan;25(1):149-60
Abstract
|
|
Levin
VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB
Superiority
of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and
vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
Int
J Radiat Oncol Biol Phys 1990 Feb;18(2):321-4
|
|
P. Z. New, S. Grossman, T.
Mikkelsen, T. Batchelor, S. Phuphanich, K. Carson, J. Fisher, M. Craig, P.
Cagnoni
Evaluation of safety and tolerance of
escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks
in patients with recurrent malignant glioma: Results of the phase I NABTT 9806
clinical trial
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1533
|
|
Pamela Z New, Stuart A Grossman, Tracy
Batchelor, Fred Hochberg, Surasak Phuphanich, Kathryn Carson, Regina Priett
Evaluation of safety and tolerance of escalating
doses of RSR13 administered with a fixed dose of BCNU every six weeks in
patients with recurrent malignant glioma: preliminary data of NABTT 9806
phase I/II clinical trial
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2098
|
|
Jennifer
A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H.
Sampson, James Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy
Walker, Holly Schweitzer, Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon
II, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Cindy
Bohlin, Christy Lentz, Henry S. Friedman
Phase 1 trial of irinotecan
plus BCNU in patients with progressive or recurrent malignant glioma
Neuro-Oncology, April 2004 Volume 6, Number 2, Pages 145 – 153. (Abstract+)
|
|
Jennifer
A. Quinn, M. Eileen Dolan, Anthony E. Pegg, Robert C. Moschel, James Pluda,
Roger E. McLendon, James Provenzale, William Petros, Sandra Tourt-Uhlig, Jeremy
N. Rich, Sridharan Gururangan, Mary L. Affronti, Waynette Buchanan, O. Michael
Colvin, Elizabeth S. Stewart, Allan H. Friedman, Darell D. Bigner, Henry S.
Friedman
Phase II Trial of BCNU Plus O6-Benzylguanine
for Patients with Recurrent or Progressive Malignant Glioma
ASCO
Proceedings, 2001 Annual Meeting, Abstract
No.251
|
|
Jeffrey J.
Raizer,
Mark G. Malkin, Martin Kleber, Lauren E. Abrey
Phase 1 study
of 28-day, low-dose temozolomide and BCNU in the treatment of malignant
gliomas after radiation therapy
Neuro-Oncology, July
2004, Vol. 6, No. 3, 247 -- 252. (Abstract+)
|
|
David
A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James
Vredenburgh, John H. Sampson, James M. Provenzale, Amy Walker, Michael
Badruddoja, Sandra Tourt-Uhlig, James E. Herndon II, Jeannette M. Dowell, Mary
Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Steven Silverman,
Cindy Bohlin, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase 2 trial of BCNU plus irinotecan in adults with
malignant glioma
Neuro-Oncology, April 2004, Volume 6, Number 2, Pages 134 – 144. (Abstract+)
|
|
Slancar
M., Wheeler H., Cook R., Levi J., Bell D., Beith J.
Increased pulmonary toxicity with scheduling
procarbazine prior to BCNU in patients with high-grade gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1459
|
|
|
The Brain Tumor Cooperative Group ; Robert G. Selker,
M.D.; William R. Shapiro, M.D.; Peter Burger, M.D.; Margaret S. Blackwood, M.S.;
Melvin Deutsch, M.D.; Vincent C. Arena, Ph.D.; John C. Van Gilder, M.D.; Julian
Wu, M.D.; Mark G. Malkin, M.D.; John Mealey, Jr., M.D.; John H. Neal, M.D.;
Jeffrey Olson, M.D.; James T. Robertson, M.D.; Gene H. Barnett, M.D.; Stephen
Bloomfield, M.D.; Robert Albright, M.D.; Fred H. Hochberg, M.D.; Emile Hiesiger,
M.D.; Sylvan Green, M.D.
The Brain
Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery,
External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy
Boost, External Radiation Therapy, and Carmustine
Neurosurgery
2002 Aug;51(2):343-55
Abstract
|
|
Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P,
Fumagalli R
Simvastatin, an inhibitor of cholesterol biosynthesis,
shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and
beta-interferon on human glioma cells
Cancer Res 1992 Aug 15;52(16):4348-55
|
|
Mark
M. Souweidane, Giuseppe Occhiogrosso, Erika B. Mark, Mark A. Edgar, Ira J.
Dunkel
Interstitial Infusion of Carmustine in the Rat
Brain Stem with Systemic Administration of O6-benzylguanine
Journal of Neuro-Oncology, 67 (3):
319-326, May 2004. (Abtract+)
|
|
Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L,
Heiskanen O, Unsgaard G, Kuurne T
Interstitial
chemotherapy with carmustine-loaded polymers for high-grade gliomas: a
randomized double-blind study
Neurosurgery
1997 Jul;41(1):44-8
|
|
Meg
Verrees, Lili Liu, Stanton L. Gerson
Interruption of base excision repair selectively enhances
temozolamide and 1,3-bis(2-chloroethyl)-nitrosurea cytotoxicity in treatment of
adult human malignant glioma cell lines
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 1548
|
|
|
Wolff JE, Berrak S, Koontz Webb SE, Zhang M
Nitrosourea efficacy in high-grade glioma: a survival gain analysis
summarizing 504 cohorts with 24193 patients
J Neurooncol. 2008 Feb 6; [Epub ahead of print]
Abstract
|
|
Carmustine implants
|
|
|
|
Attenello FJ, Mukherjee D, Datoo G, McGirt MJ,
Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H
Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma:
A 10-Year Institutional Experience
Ann Surg Oncol. 2008 Jul 18; [Epub ahead of print]
Abstract |
DB links | 
CNO 7(15)
|
|
Brem
H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M,
Brem S, Mohr G, et al.
Placebo-controlled trial of safety and efficacy of
intraoperative controlled delivery by biodegradable polymers of chemotherapy for
recurrent gliomas. The Polymer-brain Tumor Treatment Group
Lancet 1995 Apr 22;345(8956):1008-12
|
|
|
Catalán-Uribarrena G,
Bilbao-Barandica G, Pomposo-Gaztelu I, Undabeitia-Huertas J, Ruiz de
Gopegui-Ruiz E, Galbarriatu-Gutiérrez L,
Canales-Llantada M, Aurrecoechea-Obieta J, Igartua-Azkune A, Carbayo-Lozano
G.
Prognostic factors and
survival in a prospective cohort of patients with high-grade glioma treated
with carmustine wafers or temozolomide on an intention-to-treat basis.
Acta Neurochir (Wien). 2011 Oct 15;. [Epub ahead of print]
Abstract |
Reprint
|
Related articles
|
|
Allan
H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra
Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason,
Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn,
Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D
Bigner, Henry Friedman
Novel use of Gliadel for gliomas
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
|
|
Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA,
Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH,
Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS.
Phase
I study of Gliadel wafers plus temozolomide in adults with recurrent
supratentorial high-grade gliomas
Neuro-oncol 2001
Oct;3(4):246-50
|
|
|
Noël
G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, Dufour P, Kehrli
P, Maitrot D.
Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant
Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After
Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas.
Int J Radiat Oncol Biol Phys. 2011 Feb 5;. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Perry J, Chambers A, Spithoff K, Laperriere
N.
Gliadel wafers in the treatment of malignant glioma: a systematic review.
Curr Oncol. 2007
Oct;14(5):189-94.
Full
Text |
Reprint
|
|
Mark
Rosenblum, J Weingart, Eileen Dolan, S Tatter, K Judy, J Olson, E Bohan, J
Fisher
Phase
I study of Gliadel combined with a continuous intravenous infusion of
O6-benzylguanine in patients with recurrent malignant glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No.
314
|
|
|
Salvati
M, D'elia A, Frati A, Brogna C, Santoro A, Delfini R.
Safety and feasibility of the adjunct of local chemotherapy with
biodegradable carmustine (BCNU) wafers to the standard multimodal approach
to high grade gliomas at first diagnosis.
J Neurosurg Sci. 2011 Mar;55(1):1-6.
Abstract |
Related articles
|
|
Tatter SB, Shaw EG,
Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR,
Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA; New Approaches to
Brain Tumor Therapy Central Nervous System Consortium
An inflatable balloon catheter and liquid 125I
radiation source (GliaSite Radiation Therapy System) for treatment of
recurrent malignant glioma: multicenter safety and feasibility trial
J Neurosurg. 2003 Aug;99(2):297-303
|
|
|
M. Westphal, Z. Ram, V. Riddle,
D. Hilt, E. Bortey and On behalf of the Executive Committee of
the Gliadel® Study Group
Gliadel® wafer
in initial surgery for malignant glioma: long-term follow-up of a
multicenter controlled trial
Acta Neurochirurgica, Volume 148, Number 3, March 2006; DOI: DOI: 10.1007/s00701-005-0707-z
Abstract
| .gif)
News
News
|
|
Manfred
Westphal, Dana C. Hilt, Enoch Bortey, Patrick Delavault, Robert
Olivares, Peter C. Warnke, Ian R. Whittle, Juha Jääskeläinen, Zvi Ram
A phase 3 trial of local chemotherapy with
biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with
primary malignant glioma
Neuro-Oncology, April 2003, Volume 5, Number 2, Page: 79 -- 88
|
|
|
Medulloblastoma
|
|
|
|
Demetrius M.
Kokkinakis, Robert C.
Moschel, Anthony E. Pegg and S. Clifford Schold
Eradication of Human Medulloblastoma
Tumor Xenografts with a Combination of O6-Benzyl-2'-deoxyguanosine
and 1,3-Bis(2-chloroethyl)-1-nitrosourea
Clinical Cancer Research Vol. 5, 3676-3681, November 1, 1999. (PDF Full Text)
|
|
|
Oligoastrocytomas
|
|
|
|
Boiardi A, Eoli M, Salmaggi A, Pollo
B, Milanesi I, Broggi G, Silvani A
Cisplatin and BCNU chemotherapy for
anaplastic oligoastrocytomas
J
Neurooncol 2000 Aug;49(1):71-5
|
|
|
Oligodendroglioma
|
|
|
|
Richard A.
Lytle, Zhihong Jiang, Xiao Zheng, Keith M.
Rich
BCNU Down-Regulates Anti-Apoptotic Proteins Bcl-xL and Bcl-2 in
Association with Cell Death in Oligodendroglioma-Derived Cells
Journal of Neuro-Oncology, 68 (3): 233-241, July 2004. (Abstract+)
|
|
|
Primary
CNS Lymphoma
|
|
|
|
|
Illerhaus G, Marks R, Ihorst G, Guttenberger R,
Ostertag
C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.
High-dose chemotherapy with autologous
stem-cell transplantation and hyperfractionated radiotherapy as first-line
treatment of primary CNS lymphoma.
J
Clin Oncol. 2006 Aug
20;24(24):3865-70. Epub 2006 Jul 24.
Abstract
|
|
|
Pituitary
Adenomas
|
|
|
|
Laws ER Jr,
Morris AM, Maartens N
Gliadel
for pituitary adenomas and craniopharyngiomas
Neurosurgery. 2003 Aug;53(2):255-69; discussion 259-60
|
|
|
Tumors
|
|
|
|
Dolan ME, Pegg AE
O6-benzylguanine
and its role in chemotherapy
Clin Cancer Res
1997 Jun;3(6):837-47
|
|
